Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

  • Frederick A. Sirgel,
  • Robin M. Warren,
  • Erik C. Böttger,
  • Marisa Klopper,
  • Thomas C. Victor,
  • Paul D. van Helden

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks

  • Frederick A. Sirgel, 
  • Robin M. Warren, 
  • Erik C. Böttger, 
  • Marisa Klopper, 
  • Thomas C. Victor, 
  • Paul D. van Helden
PLOS
x

There is an error in Table 1. An AspTyr mutation is wrongly abbreviated as D516T (1). It should be listed as D516Y (1). Please see the corrected Table 1 here.

thumbnail
Table 1. MICs and relative resistance of rifampicin and rifabutin in M. tuberculosis.

https://doi.org/10.1371/journal.pone.0134190.t001

Reference

  1. 1. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2013) The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks. PLoS ONE 8(3): e59414. pmid:23527189